All News

ACR Best

ACR21 Best Abstracts - Day 2

Jack Cush, MD

The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).

Read Article
YouTube Still

RheumNow Podcast – ACR Convergence Begins (11.5.2021)

Jack Cush, MD

Dr. Cush reviews the news, and kicks off ACR21 learning and how to take in the annual meeting.

Read Article
guidelines.recommendations.jpg

Management of Immune-Related Adverse Events - ASCO Guideline

Jack Cush, MD

The American Society of Clinical Oncology, Inc (ASCO) has updated its guidelines and recommendations for the management of immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitor (ICPi) therapy. Below are select statements from this guideline.

Read Article
genes.jpg

Clues to Survival and Mortality with VEXAS Syndrome

ACR

New research to be presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows a relationship between genotype, bone marrow failure and survival in patients with the rare autoinflammatory disease VEXAS syndrome, which was only identified in 2020.

Read Article
Cancer.risk_.jpg

Cancer Risk in Systemic Lupus Erythematosus

Jack Cush, MD

Bernatsky and colleagues have shown cancer risk factors in incident systemic lupus erythematosus (SLE).

Researchers analyzed an SLE cohort of 1,668 patients, over an average of 9 years follow-up and found 65 cancers: 15 breast; 10 nonmelanoma skin; 7 lung; 6 hematologic; 6 prostate; 5 melanoma; 3 cervical; 3 renal; 2 each gastric, head and neck, and thyroid; and, 1 each rectal, sarcoma, thymoma, and uterine cancers.

Read Article
RheumNow Podcast square

RheumNow Podcast – #ACA: Ask Cush Anything (10.8.2021)

Jack Cush, MD

Arthritis numbers are rising, and people are finally talking about osteoarthritis. Also, ACR 2021 is just a few weeks away - are you ready? Finally, I'll review cases and questions submitted by viewers in Ask Cush Anything (#ACA). This, and nearly a dozen news items and reports, are discussed in this week's podcast. Let's begin.

Read Article
38420215_s.jpg

No Recurrent Cancer Risk With Biologic Treatment of RA

MedPage Today

Patients with rheumatoid arthritis (RA) who had a history of cancer did not have an increased risk of new or recurrent cancers if treated with biologic therapies, a meta-analysis found.

Read Article
RheumNow Podcast square

RheumNow Podcast – I Wanna New Drug.V2 (9.24.2021)

Jack Cush, MD

Almost three years ago to the day, I did a podcast entitled, "I wanna new drug." As I go over this week's podcast, I want to say it again. I want a new drug safe enough to use during pregnancy, for PMR, for GVHD, and more. I'm going to cover these, and other topics including lupus, COVID breakthrough infections, and statin use and the risk of RA, as I review the news and journal articles from the past week on RheumNow.

Read Article
What to do if pt on a TNFi develops cancer? Can you safely restart TNFi later? Depends on cancer, timing - how long ago was cancer, Rx and patient preference. Data diff from RABBIT registry vs British bio registry @RheumNow #ACR21 #ACRBest 7S413 Have a look https://t.co/q9SFKlFJzg
Janet Pope Janetbirdope ( View Tweet)
Very interesting talks by Dr. Kim and Dr. Hyrich on DMARDs and Cancer risks #ACR21 @RheumNow https://t.co/Dl5WPo7mmj
Akhil Sood MD AkhilSoodMD ( View Tweet)
This feels like an excellent starting point for Tuesday's ORAL Surveillance malignancy discussion. RWE Cohort: HR 1.01 (0.83-1.22) RCT-dup Cohort: HR 1.19 (0.86-1.64) ORAL Surveillance: HR 1.48 (1.04-2.09) Interesting day 4 ahead! great talk @SeoyoungCKim #ACR21 7S413 @RheumNow https://t.co/YSau21goMr
David Liew drdavidliew ( View Tweet)
Abst0569 #acr21 @RheumNow mortality in SpA:⬆️ overall mortality in AS (RR 1.64, 95% CI: 1.49-1.80,) but not PsA (RR: 1.12, 95% CI: 0.96-1.30). CV, resp & infection specific mortality significantly higher for PsA Cancer related mortality in PsA not higher than the gen pop

Olga Petryna DrPetryna ( View Tweet)

Retrospective study of cancer pts Rx w/ ICI and autoimmune Ab (ANA, RF, CCP, SSA/SSB, ANCA) 👉152 pts 👉59% had irAE 👉preICI Ab+⬆️odds of irAE (OR 17.5 95% CI 1.76-174, p=0.015) 👉strong assc b/t +RF and +CCP for ICD-arthritis #ACR21 Abst#0440 @Rheumnow https://t.co/kUv5ddSAnY

Links:

TheDaoIndex KDAO2011 ( View Tweet)

Large case-control study (n=8028) to identify baseline predictors of rheum irAEs after immune checkpoint inhibitor initiation for cancer. Type of cancer (melanoma, GU), combination ICI, pre-existing autoimmune disease, and recent GC use each had higher odds of rheum irAE #ACR21 https://t.co/rHI6VQ37QB
Jeffrey Sparks MD MMSc jeffsparks ( View Tweet)
Health insurance data from Korea analyzed 17,854 SLE pts & saw incr risk hematologic & solid cancers; solid (126.9/10K PY;SIR 1.8), heme (11.2/10KPYs; SIR 1.7). Most common in SLE: breast, reproductive & thyroid then liver & colon cancers https://t.co/dRs7SUwUAY

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA put a box warnings on breast implant packaging to include info that 1)Breast implants are not lifetime devices; 2) complication risk increases over time; 3) risk of anaplastic large cell lymphoma, 4) may be assoc w/ systemic Sxs https://t.co/VnpJg45PZY

Links:

Dr. John Cush RheumNow ( View Tweet)

Cancer Risk in Systemic Lupus Erythematosus https://t.co/1pzSJn62MS https://t.co/Mm1F4HCNFs

Links:

Dr. John Cush RheumNow ( View Tweet)
Having both Cancer & Systemic sclerosis (SSc) is rare. Study of 1481 SSc pts saw cancer Dx w/in 2, (1.35), 3 (2.1%) & 5 yrs (3.5%;mostly breast, GYN, Heme CA). Higher 2 yr risk w/ topoisomerase I Ab (OR 3.43), U1-RNP (5.54), but not RNA polymerase III) https://t.co/dVuchv8Afv https://t.co/azGmJYifrj

Links:

Dr. John Cush RheumNow ( View Tweet)
In case you missed it: Patients with rheumatoid arthritis (RA) who had a history of cancer did NOT have an increased risk of new or recurrent cancers if treated with biologic therapies, a meta-analysis found. #RheumNow https://t.co/jM9oiRin2M https://t.co/RknVHmZK98

Links:

Dr. John Cush RheumNow ( View Tweet)
Patients with rheumatoid arthritis (RA) who had a history of cancer did NOT have an increased risk of new or recurrent cancers if treated with biologic therapies, a meta-analysis found. #RheumNow https://t.co/jM9oiRzXUk https://t.co/XYnaalEfe2

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×